Jazz Pharma & Pharma Mar v. InvaGen & CIPLA: Zepzelca® Lurbinectedin Patent Voluntarily Dismissed
Jazz Pharmaceuticals Ireland Limited and Pharma Mar, SA brought an infringement action in the Eastern District of New York asserting US7763615B2 — covering the anticancer agent lurbinectedin (Zepzelca®) — against InvaGen Pharmaceuticals and three CIPLA entities. The case closed via voluntary dismissal just 35 days after filing, with the public record silent on whether prejudice terms were negotiated.
A 35-day Hatch-Waxman skirmish over Zepzelca® ends quietly
On 12 September 2024, Jazz Pharmaceuticals Ireland Limited and its licensor Pharma Mar, SA filed suit in the U.S. District Court for the Eastern District of New York (Case No. 2:24-cv-06416), asserting infringement of US7763615B2 against InvaGen Pharmaceuticals, Inc. and three affiliated CIPLA entities — CIPLA Limited, CIPLA (EU) LIMITED, and CIPLA USA, Inc. The patent-in-suit covers lurbinectedin, the active pharmaceutical ingredient marketed as Zepzelca®, a 4 mg lyophilized powder for injection used in relapsed or refractory small cell lung cancer.
The case was terminated on 17 October 2024 — just 35 days after filing — through a Notice of Voluntary Dismissal. The public court record does not specify whether the dismissal was entered with or without prejudice. Under Federal Rule of Civil Procedure 41(a)(1), a plaintiff may file a notice of voluntary dismissal before the opposing party serves an answer or motion for summary judgment, meaning the procedural posture is consistent with pre-answer resolution. Without an explicit prejudice designation in the record, the full legal implications for either party remain unclear.
The compressed timeline — filing to closure in 35 days — is notably short even for early-stage pharmaceutical patent disputes and suggests resolution likely occurred outside the courtroom, possibly through licensing discussions, a consent order, or an agreement tied to the defendants’ ANDA or regulatory strategy. Whether the dismissal reflects a negotiated standstill, a settlement in principle, or a tactical withdrawal cannot be confirmed from the public record alone. The absence of any defendant law firm entry in the docket further suggests the matter may have been resolved before formal defence counsel was engaged.
Filing to Voluntary dismissal in 35 days
35 days — resolved well before any substantive motion practice or scheduling order
Voluntarily dismissed: what the record does and does not tell us
Voluntary dismissal under Rule 41 — pre-answer exit
A Notice of Voluntary Dismissal filed under FRCP 41(a)(1) allows a plaintiff to exit a case without a court order, provided the defendant has not yet answered. The 35-day timeline here is consistent with pre-answer filing. Critically, no prejudice designation appears in the public record — meaning it is unclear whether plaintiffs retain the right to refile the same claims against the same defendants.
Rule 41(a)(1) — pre-answer dismissalWith or without prejudice? The record is silent
Dismissals ‘with prejudice’ permanently bar refiling the same claims, functioning as a final judgment on the merits. Dismissals ‘without prejudice’ preserve the plaintiff’s right to sue again. The public docket for this case does not specify which applies. Where no prejudice term is stated in a Rule 41(a)(1) notice, courts typically treat the dismissal as without prejudice by default — but this should not be assumed without reviewing the actual filing.
Prejudice terms unconfirmedJazz and Pharma Mar retain strategic optionality
If the dismissal is without prejudice — the more probable default outcome — Jazz Pharmaceuticals and Pharma Mar may refile against InvaGen or the CIPLA entities should commercial or regulatory circumstances change. This preserves enforcement leverage while keeping terms of any parallel negotiation confidential. The absence of a settlement agreement in the public record is consistent with this reading.
Enforcement optionality preservedCIPLA and InvaGen avoid early adverse findings
For InvaGen and the CIPLA group, voluntary dismissal before answer avoids any invalidity or non-infringement determination on the merits. No judgment on US7763615B2 was entered, meaning the patent’s enforceability against these defendants remains legally untested by this action. Future ANDA or commercial launch decisions will still need to account for the patent’s expiry date and any Orange Book listing status.
No merits ruling on validityFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Jazz Pharmaceuticals Ireland Limited | Individual | Biopharmaceutical patent holder — co-owner/licensor of US7763615B2 covering lurbinectedinSearch in Eureka ↗ |
| Co-Plaintiff | Pharma Mar, SA | Company | Search in Eureka ↗ |
| Defendant | Invagen Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer (InvaGen/CIPLA group) — likely ANDA filer for Zepzelca®Search in Eureka ↗ |
| Co-Defendant | CIPLA Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | CIPLA (EU) LIMITED | Individual | Search in Eureka ↗ |
| Co-Defendant | CIPLA USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Damien Noel Dombrowski | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New York Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Notice of Voluntary Dismissal ends the action without any merits adjudication. No findings of infringement, validity, or claim construction were entered. The absence of a prejudice designation in the filed notice leaves the door open to refiling, subject to any private agreement between the parties. Counsel reviewing this docket should note that the 35-day window is consistent with pre-answer dismissal under FRCP 41(a)(1), which carries different default prejudice rules than a court-ordered dismissal under Rule 41(b).
US7763615B2 — Lurbinectedin (Zepzelca®) anticancer compound
US7763615B2 covers lurbinectedin, a selective inhibitor of oncogenic transcription factors belonging to the trabectedin family of marine-derived anticancer compounds. The patent is held in the context of Zepzelca® (lurbinectedin) for injection — a 4 mg lyophilized powder approved by the FDA for adult patients with relapsed or refractory small cell lung cancer who have received prior platinum-based chemotherapy. The application number US10/485536 indicates an early-2000s priority date, suggesting the compound patent has a substantial but finite remaining life span.
Lurbinectedin represents a commercial asset of significant value to both Jazz Pharmaceuticals (commercialisation rights in the US) and Pharma Mar (originator and co-plaintiff). As a biologically derived small molecule with a structurally complex synthesis pathway, generic replication presents technical barriers — but ANDA filings from manufacturers such as InvaGen/CIPLA signal that the market exclusivity window is being actively contested. Any entity developing or marketing a generic lurbinectedin injection must account for US7763615B2 and any associated method-of-use or formulation patents listed in the Orange Book.
Should you run an FTO analysis against US7763615B2?
Any pharmaceutical company developing, manufacturing, or seeking to commercialise a generic or biosimilar lurbinectedin injection product in the United States should treat US7763615B2 as a primary FTO target. This case confirms that Jazz Pharmaceuticals and Pharma Mar are prepared to enforce the patent through EDNY litigation — and the swift dismissal here does not indicate an unwillingness to litigate, but may instead reflect a confidential resolution that preserved their enforcement posture.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map the full claim scope of US7763615B2, identify related family members, review Orange Book listings, and assess prosecution history estoppel — all from a single workflow. Eureka’s prior art analysis tools can also surface any post-grant challenge history or reexamination proceedings that may affect claim scope before you invest in ANDA preparation or formulation development.
Run a freedom-to-operate analysis on US7763615B2 to assess your product’s exposure
Run FTO in Eureka →Similar lurbinectedin and oncology ANDA patent cases
Related Hatch-Waxman infringement actions asserting anticancer compound patents in U.S. district courts, including EDNY filings involving Jazz Pharmaceuticals or Pharma Mar.
What this case signals for the Hatch-Waxman oncology IP landscape
A 35-day lifecycle in an ANDA-adjacent oncology case rarely reflects weakness — it typically signals rapid off-docket resolution.
Ultra-short timelines in pharma patent cases often reflect parallel negotiations
When a pharmaceutical infringement action closes in under 40 days with no answer filed and no prejudice stated, the most commercially plausible explanation is a negotiated resolution — licensing, consent injunction, or launch-delay agreement. IP teams monitoring Zepzelca® competition should treat this as a signal to review InvaGen/CIPLA’s ANDA status and any 30-month stay implications.
US7763615B2 remains unchallenged on validity by this action
Because no answer or counterclaim was filed before dismissal, the defendants raised no invalidity or non-infringement defences on the record. US7763615B2 exits this litigation with its enforceability legally intact. Competitors or follow-on generic filers cannot rely on any court finding from this case to design around the patent or challenge its Orange Book listing.
Limited v Invagen — key questions answered
The patent asserted is US7763615B2, covering lurbinectedin — the active ingredient in Zepzelca® (4 mg lyophilized powder for injection). The case was filed by Jazz Pharmaceuticals Ireland Limited and Pharma Mar, SA against InvaGen Pharmaceuticals and three CIPLA entities in the Eastern District of New York.
The case was dismissed 35 days after filing via a Notice of Voluntary Dismissal. This timeline is consistent with pre-answer resolution, suggesting the parties may have reached a private agreement — such as a licensing arrangement, consent order, or delayed-launch agreement — outside the public record. No prejudice terms were stated in the filed notice.
The public record does not specify. The docket reflects only a Notice of Voluntary Dismissal under FRCP 41(a)(1) without an explicit prejudice designation. Under default FRCP 41(a)(1) principles, such dismissals are typically treated as without prejudice, but practitioners should review the actual filed document for any qualifying language.
No. Because the case was dismissed before any answer or counterclaim was filed, no invalidity or non-infringement findings were entered. US7763615B2 exits this litigation with its enforceability legally intact. The patent has not been adjudicated invalid, unenforceable, or not infringed by this action.
Plaintiffs named CIPLA Limited (India), CIPLA (EU) LIMITED, and CIPLA USA, Inc. alongside InvaGen Pharmaceuticals. This multi-entity approach is consistent with Hatch-Waxman strategy where the ANDA filer, its international parent, and US distribution affiliate may each bear responsibility for commercial acts of infringement. Naming multiple entities reduces the risk of jurisdictional gaps if the case had proceeded.
PatSnap Eureka searches patents and litigation data to answer instantly.